1)The National Institute for Health and Care Excellence:Epilepsies:diagnosis and management NICE Clinical Guideline(CG137). 2019 https://www.nice.org.uk/guidance/cg137(2020年3月20日閲覧)
2)The National Institute for Health and Care Excellence:Epilepsies:diagnosis and management NICE Clinical Guideline(CG137). Appendix D:Differential diagnosis of epilepsy in children, young people and adults. 2019 https://www.nice.org.uk/guidance/cg137/resources/appendix-d-differential-diagnosis-of-epilepsy-in-children-young-people-and-adults-pdf-4427572717(2020年3月20日閲覧)
3)Shih JJ, Whitlock JB, Chimato N, et al:Epilepsy treatment in adults and adolescents:expert opinion. Epilepsy Behav 69:186-222, 2017
4)日本神経学会:てんかん診療ガイドライン2018. 医学書院, 2018 https://www.neurology-jp.org/guidelinem/tenkan_2018.html(2020年3月20日閲覧)
5)Meador KJ, Baker GA, Browning N, et al:Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med 360:1597-1605, 2009
6)Meador KJ, Baker GA, Browning N, et al:Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years(NEAD study):a prospective observational study. Lancet Neurol 12:244-252, 2013
7)Specchio LM, Gambardella A, Giallonardo AT, et al:Open label, long-term, pragmatic study on levetiracetam in the treatment of juvenile myoclonic epilepsy. Epilepsy Res 71:32-39, 2006
8)Cao J, Lin XX, Ma XM, et al:The efficacy and safety of lamotrigine for absence seizures in children and adolescents:a systematic review and meta-analysis. J Clin Neurosci 71:199-204, 2020
9)Holmes LB, Harvey EA, Coull BA, et al:The teratogenicity of anticonvulsant drugs. N Engl J Med 344:1132-1138, 2001